Innate Pharma S.A. (IPHA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:10PM EDT. Market open.
| Previous close | 2.5050 |
| Open | 2.6100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.5000 - 2.6500 |
| 52-week range | 1.8100 - 3.5700 |
| Volume | |
| Avg. volume | 8,837 |
| Market cap | 214.231M |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Insider Monkey
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]
- Zacks
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.
© 2024 Yahoo. All rights reserved.